SELLAS Life Sciences Presents Positive Key Immunobiological
Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14...
Source: globenewswire.com
Page 35 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Merck Sharp Today - Breaking & Trending Today
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak - Evaxion Biotech (NASDAQ:EVAX)
EVX-01 is Evaxion's lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor Adnan Khattak
Source: benzinga.com
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial ...
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial ...
Source: pr-inside.com
Sociodemographic characteristics and longitudinal progression of multimorbidity: A multistate modelling analysis of a large primary care records dataset in England
In this multistate modelling analysis, Sida Chen and colleagues examine sociodemographic characteristics and longitudinal progression of multimorbidity using data from primary care records in England
Source: plos.org
Belzutifan Outperforms Everolimus in Previously Treated, Advanced RCC
Belzutifan improved outcomes over everolimus in a phase 3 trial of patients with previously treated, advanced clear cell RCC.
Source: oncologynurseadvisor.com